Search

Your search keyword '"Malaka Ameratunga"' showing total 64 results

Search Constraints

Start Over You searched for: Author "Malaka Ameratunga" Remove constraint Author: "Malaka Ameratunga"
64 results on '"Malaka Ameratunga"'

Search Results

1. Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma

2. Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Catalog

Books, media, physical & digital resources

3. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

4. Personalized Cancer Immunotherapy: Today's Challenge and Tomorrow's Promise

5. Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach

6. PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.

7. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma

8. Figure S1 from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

9. Table S1 from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

10. Data from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

11. Supplementary Figure Legends from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

13. Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

15. A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers

16. The cytosolic role of EZH2-IMPDH2 complex in melanoma progression and metastasis via GTP regulation

17. Cytosolic EZH2-IMPDH2 complex regulates melanoma progression and metastasis via GTP regulation

18. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

19. Combination of BRAF and MEK inhibition in BRAF V600E mutant low‐grade ganglioglioma

20. EZH2 Abundance Regulated by UHRF1/UBE2L6/UBR4 Ubiquitin System is the Potential Therapeutic Target to Trigger Pigmented Phenotype in Melanoma

21. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

22. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

23. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

24. CNS cancer immunity cycle and strategies to target this for glioblastoma

25. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

26. The off-target kinase landscape of clinical PARP inhibitors

27. Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors

28. Abstract CT140: Proof-of-concept evidence of immune modulation by blockade of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway in the phase I dose escalation study of Ipatasertib (Ipa) in combination with atezolizumab (A) in patients (pts) with advanced solid tumors (Ice-CAP)

29. Anti‐angiogenic therapy for high‐grade glioma

30. EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS

31. To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity

32. Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials

33. Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma

34. A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting

35. Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis

36. Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors

37. Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience

38. PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination

39. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

40. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

41. Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital

42. P3.03-004 Genome-Wide Copy Number Aberrations in Mesothelioma and Its Correlation with Tumor Microenvironment including PD-L1 Expression

43. ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414

44. Hypopharyngeal large cell neuroendocrine carcinoma

45. RARE-01PROLONGED DISEASE CONTROL WITH MEK INHIBITOR IN NEUROFIBROMATOSIS TYPE I ASSOCIATED GLIOBLASTOMA

46. Fever in melanoma: new drugs or bugs?

47. P2.02-039 Spatial Heterogeneity of Immunological Markers Between Cores and Complete NSCLC Sections Using Multispectral Fluorescent IHC

48. Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy

49. Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit

50. Prospective study of the impact of neuro-oncology multi-disciplinary meetings on clinical decision making